News
NRAS mutations predict immunotherapy outcomes in melanoma patients
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Patients with advanced melanoma and mutations in the NRAS gene had better responses to immunotherapy than did those without...
News
Liquid biopsy consistent with tumor biopsy for NSCLC
- Author:
- Jennifer Kelly Shepphird
Key clinical point: The EGFR mutation L858R detected in both tissue and cfDNA predicted shorter OS and PFS than did the exon 19 deletion. Major...
News
Oral Bisphosphonates Linked with Lower Risk of Endometrial Cancer
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial...
News
Oral bisphosphonates linked with lower risk of endometrial cancer
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial...
News
Bevacizumab fails to improve outcomes for metastatic uterine leiomyosarcoma
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Bevacizumab added to gemcitabine-docetaxel did not improve outcomes in patients with uterine leiomyosarcoma. Major finding:...
News
Uterine cancer low in myomectomy with power morcellation
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Among women who underwent myomectomy, the prevalence of cancers was low but increased with age. Major finding: Rates of...
News
Bevacizumab plus ET failed to improve PFS in HER2-negative, HR-positive BC
- Author:
- Jennifer Kelly Shepphird
Key clinical point: In women with HER2-negative, hormone receptor–positive breast cancer, the addition of bevacizumab to endocrine therapy did not...
News
Time and money spent locating unknown primary tumor site might be better spent on genomic analyses
- Author:
- Jennifer Kelly Shepphird
Key clinical point: The resources and time spent to locate the primary tumor site in patients with metastatic unknown primary cancer might be...
News
Overall survival plateaus at 3 years for ipilimumab-treated melanoma patients
- Author:
- Jennifer Kelly Shepphird
Key clinical point: Ipilimumab-treated advanced melanoma patients alive at 3 years tend to have good long-term outcomes. Major finding: Around...